What is the recommended dose of adenosine (adenosine) for a pediatric patient with supraventricular tachycardia (SVT)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Adenosine Dosing for Pediatric Supraventricular Tachycardia

For pediatric SVT, start with 0.1 mg/kg (100 mcg/kg) as a rapid IV bolus, followed by 0.2 mg/kg if the first dose fails, up to a maximum of 0.3 mg/kg (300 mcg/kg). 1, 2

Dosing Protocol

  • Initial dose: 0.1 mg/kg (100 mcg/kg) administered as the most rapid IV push possible 1, 2
  • Second dose: 0.2 mg/kg (200 mcg/kg) if the first dose is ineffective 1, 2
  • Maximum dose: 0.3 mg/kg (300 mcg/kg) 1, 2
  • The initial pediatric dose is substantially higher than the adult starting dose of 6 mg, reflecting the higher doses needed in children 3, 1

Critical Administration Technique

  • Use a large, proximal peripheral vein (antecubital preferred) 1
  • Administer as the most rapid IV push possible followed immediately by a rapid 5-10 mL saline flush 1, 2
  • The rapid administration and flush are essential because adenosine has an extremely short half-life of 0.6-10 seconds 4

Expected Efficacy

  • Overall cardioversion success rate: 72-88% for all SVT types 1, 5
  • Success rate for AV node-dependent SVT: 79-96% 1, 5
  • Adenosine is superior to digoxin (61-71% success) with approximately 90% success when used appropriately 1
  • Most successful conversions occur with medium (0.1-0.2 mg/kg) to high (≥0.2 mg/kg) doses 5

When to Use Adenosine

Adenosine is the drug of choice (Class I recommendation) specifically for supraventricular tachycardia with narrow QRS complexes (<0.09 seconds). 6, 2

  • Attempt vagal stimulation first (such as applying ice to the face without occluding the airway) unless the patient is hemodynamically unstable or this will unduly delay treatment 7, 2
  • For hemodynamically unstable patients, proceed directly to synchronized cardioversion at 0.5-1 J/kg 7

Critical Pitfalls to Avoid

Never Use Adenosine for Wide-Complex Tachycardia

Never assume wide-complex tachycardia (QRS >0.09 seconds) is supraventricular—treat as ventricular tachycardia until proven otherwise. 6, 2

  • The diagnostic use of adenosine in wide-complex tachycardia carries significant risk if the rhythm is actually VT 6
  • For unstable VT, synchronized electrical cardioversion is the preferred first therapy 6

Avoid Verapamil in Infants

Never use verapamil in infants due to multiple reports of cardiovascular collapse and death. 7, 1, 2

  • Verapamil (0.1-0.3 mg/kg) may be used in older children but should not be used in infants without expert consultation due to potential myocardial depression, hypotension, and cardiac arrest 7

Management of Refractory SVT

If adenosine fails to convert SVT:

  • Procainamide has higher success rates than amiodarone for refractory pediatric SVT with equal adverse effects 1, 2
  • Consider amiodarone 5 mg/kg IV/IO or procainamide 15 mg/kg IV/IO for SVT unresponsive to vagal maneuvers and adenosine 7
  • Synchronized cardioversion is preferred for unstable patients or when pharmacologic therapy fails, starting at 0.5-1 J/kg and increasing to 2 J/kg if needed 7, 1, 2

Adverse Effects

  • Adverse effects occur in approximately 22% of patients but are typically transient and mild 5
  • Common effects include flushing, chest discomfort, sinus bradycardia, varying degrees of AV block, irritability, and nondistressing alterations in respiratory pattern 4, 5
  • All adverse effects resolve within seconds to minutes due to adenosine's extremely short half-life 4, 8
  • Reinitiation of SVT within 5 seconds occurs in approximately 13% of successfully terminated episodes, requiring consideration of prophylactic antiarrhythmic therapy 9

Monitoring Requirements

  • Continuous ECG monitoring is essential before, during, and after adenosine administration 2, 4
  • Monitor blood pressure, respiratory status, and capillary refill 4
  • Have resuscitative equipment and personnel immediately available 7

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.